Open AccessRibociclib in 1st line HR+ breast cancer treatment
Author(s) -
Lyudmila Zhukova,
Жукова Людмила Григорьевна,
Inna Ganshina,
Ганьшина Инна Петровна,
О. О. Гордеева,
Гордеева Ольга Олеговна,
Е. В. Лубенникова,
Лубенникова Елена Владимировна
Publication year - 2018
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/1815-1434_2018.2.38-41
Subject(s) - medicine , breast cancer , clinical trial , cancer , clinical practice , oncology , intensive care medicine , family medicine
Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.